Skip to content

Saxenda 1.8 mg: week 3

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Saxenda 1.8 mg daily is the week 3 dose on the FDA label's step-up schedule, after 1.2 mg and before 2.4 mg in week 4. For adults, it's a titration dose only, meaning a step on the way up. Novo Nordisk's list price for Saxenda is $1,349.02.

Source: List price

Key takeaways

  • Saxenda 1.8 mg is the week 3 dose. For adults, it's for stepping up only.
  • On schedule, your first pen normally runs out this week, so have a second pen ready.
  • Check you have enough pens for the remaining weeks. A gap of more than 3 days restarts you at 0.6 mg.
  • The label doesn't recommend using Saxenda with other liraglutide products or other GLP-1 medicines.
  • Novo Nordisk's list price is $1,349.02, the same at every dose.

What the label says about Saxenda 1.8 mg

Once dailyNot a maintenance dose on the labelAt least 7 days before any increase

Week 3.

Table 1. Dosage Escalation Schedule: Week 3, 1.8 mg.

Comes as: Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens).

FDA label: Revised: 6/2026 (DailyMed version 22)

Saxenda dose schedule from the label

SaxendaRevised: 6/2026 (DailyMed version 22)

  1. 10.6 mg7 daysStart
  2. 21.2 mg7 days
  3. 31.8 mg7 daysThis page
  4. 42.4 mg7 days
  5. 53 mgongoingMaintenance dose

Put it on a calendar with the titration schedule builder. Only your prescriber decides when, and whether, your dose changes.

Supply per fill

Pack sizes from the "How supplied" section of the Saxenda label
FormDoses per deviceDoses per fillDays per fillFills per year
Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens)18 mg per pen303012

Track run-out and refill dates with the supply tracker.

Saxenda 1.8 mg: every way to pay, cheapest first

This table uses the 1.8 mg dose. Prices can differ at other doses, so use the cost calculator for yours. Swipe the table sideways to see conditions and sources.

No price is listed for Saxenda 1.8 mg.

Savings-card and Medicare prices apply only if you are eligible. "From" prices that telehealth providers advertise are shown only at the lowest strength.

If you miss a dose of Saxenda

  • If you miss a daily shot, just take your next scheduled dose as normal; never take an extra or bigger dose to catch up.

    If a dose is missed, resume the once-daily regimen as prescribed with the next scheduled dose. Do not administer an extra dose or increase the dose to make up for the missed dose.
  • If it has been more than 3 days since your last shot, restart at the 0.6 mg starting dose and work back up week by week to reduce stomach side effects.

    If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.

Enter your own dates in the missed-dose helper. If you are unsure, call your prescriber or pharmacist; never take two doses to catch up.

Week 3 on Saxenda is the middle of the ladder: two steps behind you and two ahead. The 1.8 mg dose also stands out because the largest safety trial cited on the Saxenda label was run at this dose of liraglutide. The Saxenda guide covers the medicine in general.

The label’s place for 1.8 mg

The step-up table assigns 1.8 mg daily to week 3. You reach it after a week on 1.2 mg, and the next step is 2.4 mg in week 4. The label says the step-ups are followed to reduce the likelihood of gastrointestinal (stomach and gut) side effects. If an increased dose isn’t tolerated, a delay of approximately one additional week can be considered.

For adults, 1.8 mg isn’t somewhere the Saxenda label lets you stop. Lower dosages are for titration, meaning stepping up, only, and the recommended dosage is 3 mg.

Use the titration schedule tool for your dates. The dosing guide sets Saxenda’s weekly steps beside other medicines.

The LEADER trial was run at 1.8 mg

The Saxenda label reports a cardiovascular outcomes trial of liraglutide 1.8 mg, called LEADER, which tracked heart and blood vessel events. It followed 9,340 patients for a median of 3.5 years. No increased risk of major adverse cardiovascular events was seen with liraglutide 1.8 mg: 13.0% of patients on it had a primary event, one of the serious events the trial counted, against 14.9% on placebo.

Two cautions keep this in proportion. The trial was at 1.8 mg, not at the 3 mg adult Saxenda dosage. And the label separately says that using Saxenda with other liraglutide-containing products isn’t recommended, so the trial’s dose isn’t a reason to combine or substitute products.

Supply: the week the pen changes

Week 3 at 1.8 mg uses 12.6 mg across seven days. A pen holds 18 mg, and on paper the first two weeks have already used 12.6 mg of your first pen. That leaves 5.4 mg, or three doses of 1.8 mg. So on schedule, week 3 is normally when your first pen runs out and you start a second.

That has a practical side. Have the new pen on hand before the old one is empty. Each pen has its own 30-day in-use limit from its first use. The label allows a pen in use to be kept at room temperature or in a refrigerator for those 30 days. The supply tracker follows each pen separately.

Price at 1.8 mg

The Saxenda price doesn’t depend on the dose. The published figure is the list price of $1,349.02, which Novo Nordisk states without a supply period. There’s no manufacturer savings offer for new patients: it closed to new enrollees on June 30, 2023.

In week 3 the cost question is mostly about quantity. Check that the number of pens dispensed carries you through the remaining step-up weeks without a gap, because a gap of more than 3 days sends the schedule back to 0.6 mg. The Saxenda cost page covers insurance and cash routes.

Forms that carry 1.8 mg

Under the Saxenda name, 1.8 mg is a setting on the multi-dose pen, the third of five. Saxenda has no other form.

Frequently asked questions

Is 1.8 mg an approved long-term dose of Saxenda?

Not for adults. The Saxenda label says the recommended adult dosage is 3 mg daily and that lower dosages are for titration (stepping up) only. In its step-up table, 1.8 mg is the week 3 dose. Our label record classes it as a step-up dose, not a maintenance dose.

Why does the Saxenda label mention a trial of liraglutide 1.8 mg?

The label reports the LEADER trial, which studied liraglutide 1.8 mg in 9,340 patients for a median of 3.5 years. No increased risk of major adverse cardiovascular events (serious heart and blood vessel events) was seen: they occurred in 13.0% on liraglutide 1.8 mg and 14.9% on placebo. That trial wasn't run at the 3 mg Saxenda dosage.

How many 1.8 mg doses does a Saxenda pen hold?

A pen contains 18 mg of liraglutide, which is ten doses of 1.8 mg on paper. On the label's schedule, you take 1.8 mg for only seven days, usually partly from a pen you already started in weeks 1 and 2. Your pharmacist can confirm how your pens will run.

Can I use another liraglutide product with Saxenda?

The label says no. Saxenda contains liraglutide, and using it with other liraglutide-containing products or with any other GLP-1 receptor agonist (the medicine class Saxenda belongs to) isn't recommended. Tell your prescriber and pharmacist about every medicine you take so they can check.

Sources (6)

  1. 1.
    FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
    “It contains 18 mg of liraglutide, and you can select doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3 mg.”
  2. 2.
    FDA label (DailyMed): Saxenda prescribing information, section 6.1
    “No increased risk for MACE was observed with liraglutide 1.8 mg. The total number of primary component MACE endpoints was 1,302 [608 (13.0%) with liraglutide 1.8 mg and 694 (14.9%) with placebo].”
  3. 3.
    FDA label (DailyMed): Saxenda prescribing information, section 1
    “SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  4. 4.
    FDA label (DailyMed): Saxenda prescribing information, section 16
    “After initial use of the SAXENDA pen, the pen can be stored for 30 days at controlled room temperature 59°F to 86°F (15°C to 30°C) or in a refrigerator 36°F to 46°F (2°C to 8°C). Keep the pen cap on when not in use. Protect SAXENDA from excessive heat and sunlight.”
  5. 5.
  6. 6.